Actively Recruiting
A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
Led by Ruijin Hospital · Updated on 2024-07-10
32
Participants Needed
1
Research Sites
213 weeks
Total Duration
On this page
Sponsors
R
Ruijin Hospital
Lead Sponsor
N
Nanjing Legend Biotech Co.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a prospective, single-arm, open-label, exploratory clinical study of LCAR-HL30 in adult subjects with relapsed/refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma.
CONDITIONS
Official Title
A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects voluntarily participate in clinical research.
- Aged 18 to 75 years, either sex.
- Eastern Cooperative Oncology Group (ECOG) score 0-1 for dose escalation phase; ECOG score 0-2 for dose expansion period.
- Histologically confirmed Hodgkin's lymphoma or Anaplastic large cell lymphoma with positive CD30 expression.
- At least one evaluable tumor lesion according to Lugano 2014 criteria.
- Expected survival of at least 3 months.
- Clinical laboratory values during screening meet study criteria.
- Use of effective contraception.
You will not qualify if you...
- Prior antitumor therapy with insufficient washout period.
- Previous treatment with CAR-T therapy or allogeneic hematopoietic stem cell transplantation.
- Severe underlying diseases.
- Positive for Hepatitis B surface antigen, Hepatitis B DNA, Hepatitis C RNA, or HIV antibody.
- Presence of other serious pre-existing medical conditions that may limit participation as judged by the investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Actively Recruiting
Research Team
J
Jianqing Mi
CONTACT
W
Wenyan Yu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here